Influence of ovarian hormones on urogenital infection

Sexually Transmitted Infections

Volumn 74, Issue 1, 1998, Pages 11-19

  Sonnex, C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Oestrogen; Progesterone; Urogenital infection

Indexed keywords

ESTROGEN; PROGESTERONE;

HELPER CELL; HORMONAL REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; KILLER CELL; PATHOGENICITY; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; UROGENITAL TRACT INFECTION;

EID: 0031920782     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.74.1.11     Document Type: Review

References (189)

1. Inman RD. Immunologic sex differences and the female preponderance in systemic lupus erythematosus. Arthritis Rheum 1978;21:849-52.
2. Grossman CJ. Regulation of the immune system by sex steroids. Endocrin Rev 1984;5:435-55.
3. Dwyer JM, Knox GE, Mangi RJ. Cell mediated immunity in healthy women taking oral contraceptives. Yale J Biol Med 1975;48:91-5.
4. Tubiana N, Mishal Z, leCaer F, et al. Quantification of oestradiol binding at the surface of human lymphocytes by flow cytofluorimetry. Br J Cancer 1986;54:501-14.
5. Tubiana N, Derre M, Carcassonne Y, Martin PM. Sex steroid binding to human lymphocytes plasma membrane. Br J Cancer 1984;49:531-6.
6. Pfeifer RW, Patterson RM. Modulation of lectin-stimulated lymphocyte agglutination and mitogenesis by estrogen metabolites: effects on early events of lymphocyte activation. Arch Toxicol 1986;58:157-64.
7. Cohen JHM, Daniel L, Cordier G, Saez S, Revillard J-P. Sex steroid receptors in peripheral T cells: absence of androgen receptor and restriction of estrogen receptors to OKT8-positive cells. J Immunol 1983;131:2767-71.
8. Stimson WH. Oestrogen and human T lymphocytes: presence of specific receptors in the T-suppressor/cytotoxic subset. Scand J Immunol 1988;28:345-50.
9. Daniel L, Sovweine G, Monier JC, Saez S. Specific estrogen binding sites in human lymphoid cells and thymic cells. J Steroid Biochem 1983;18:559-63.
10. Weusten JJA, Blankenstein MA, Gmelig-Meyerling FHJ, et al. Presence of oestrogen receptors in human blood mononuclear cells and thymocytes. Acta Endocrin (Copenh) 1986;112:409-14.
11. Nilsson B, Carlsson S, Damber MK, et al. Specific binding of 17-beta estradiol in the human thymus. Am J Obstet Gynecol 1984;149:544-7.
12. Mandeville R, Sombo FM, Rocheleau N. Natural cell mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG. Cancer Immunol Immunother 1983;15:17-22.
13. Baker DA, Salvatore W, Milch PO. Effect of low-dose oral contraceptives on natural killer cell activity. Contraception 1989;39:119-24.
14. Gabrilovac J, Zadielovic J, Osmak M, et al. NK cell activity and estrogen levels during normal human pregnancy. Gynecol Obstet Invest 1988;25:165-72.
15. Ferguson MM, McDonald FG. Oestrogen as an inhibitor of human NK cell cytolysis. FEBS Lett 1985;191:145-8.
16. Seaman WE, Blackman MA, Gindhart TD, et al. β-Estradiol reduces natural killer cells in mice. J Immunol 1978;121: 2193-8.
17. Callewaert DM, Moudgil VK, Radcliff G, Waite R. Hormone specific regulation of natural killer cells by cortisol. Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation. FEBS Lett 1991;285:108-10.
18. Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L. Estrogen and antiestrogen modulation of levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol 1987;106:191-202.
19. Trinchieri G, Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab Invest 1984;50:489-513.
20. Myers MJ, Petersen BH. Estradiol induced alterations of the immune system. 1 Enhancement of IgM production. Int J Immunopharmacol 1985;7:207-13.
21. Cotton DJ, Seligmann B, O'Brien WF, Gallin JI. Selective defect in human neutrophil superoxide anion generation elicited by the chemoattractant N-formylmethionylleucyl-phenylalanine in pregnancy. J Infect Dis 1983;148:194-9.
22. Bodel P, Dillard GM Jr, Kaplan SS, Malawista SE. Anti-inflammatory effects of estradiol on human blood leukocytes. J Lab Clin Med 1972;80:373-84.
23. Sivam G, Cohen MS, Dodd RC, Gray TK. 17β-estradiol inhibits the oxidative metabolism of U937 cells indirectly via lymphocytes. Endocrinology 1987;121:853-7.
24. Roth JA, Kaeberle ML, Appell LH, Nachreiner RF. Association of increased estradiol and progesterone blood values with altered bovine polymorphonuclear leucocyte function. Am J Vet Res 1983;44:247-53.
25. Nilsson B, Damber MG, Von Schoultz B. Effect of estrogen/progestogen combinations on polymorphonuclear leucocyte chemotaxis. Acta Obstet Gynecol Scand 1980;59:165-8.
26. Elstein M. Functions and physical properties of mucus in the female genital tract. Br Med Bull 1978;34:83-7.
27. Gibbons RA. Mucus of the mamallian genital tract. Br Med Bull 1978;34:34-8.
28. Ahmed SA, Dauphinee MJ, Monotoya AI, Tala N. Estrogen induces normal murine CD5+ B cells to produce autoantibodies. J Immunol 1989;142:2647-53.
29. Brick JE, Wilson DA, Walker SE. Hormonal modulation of responses to T-dependent and T-independent antigens in autoimmune NZB/NZW mice. J Immunol 1985;134:3693-8.
30. Stimson WH, Hunter IC. Oestrogen-induced immunoregulation mediated through the thymus. J Clin Lab Immunol 1980;4:27-33.
31. Flurkey K, Eskinazi DP, Finch CE. Estradiol regulates cell surface immunoglobulin in old mice. Dev Comp Immunol 1986;10:85-91.
32. Paavonen T, Andersson LC, Adlercreutz H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated culture. J Exp Med 1981;154:1935-45.
33. Kalman B, Olsson O, Link H, Kam-Hansen S. Estradiol potentiates pokeweed mitogen-induced B cell stimulation in multiple sclerosis and healthy subjects. Acta Neurol Scand 1989;79:340-6.
34. Mizoguchi Y, Ikemoto Y, Yamamoto S, Morisawa S. Studies on the effects of estrogen on the antibody response in asymptomatic HB virus carrier. Hepatogastroenterology 1985;32:109-12.
35. Sthoeger ZM, Chiorazzi N, Lahita FG. Regulation of the immune response by sex hormones. 1 In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 1988;141:91-8.
36. Mori H, Sawairi M, Itoh N, Hanabayashi T, Tamaya T. Effects of sex steroids on immunoglobulin M production by Epstein-Barr virus transformed B-cell line SKW6-CL4. J In Vitro Fert Embryo Transfer 1991;8:329-35.
37. Stimson WH. Serum proteins, steroids and the maternal immune response. In: Wegmann TG, Gill TJ, eds. Immunology of reproduction. Oxford: Oxford University Press, 1983:281-301.
38. Malaise MG, Franchimont P, Mahieu PR. Evidence that the phagocytosis mediated by the peanut agglutinin-like activity of IgG (Fc) receptors of human monocytes is selectively modulated by estradiol and natural estrogens. J Clin Immunol 1988;8:495-502.
39. Potlshin W, Shelegiia GSh, Mkhitarov VA. Effect of foliculin and estradiol-dipropionate on the phagocytic properties of the blood neutrophils of the female white rats. Sechenov Physiol J USSR 1986;72:221-3.
40. Polan ML, Daniele A, Kuo A. Gonadal steroids modulate human monocyte interleukin-1 activity. Fertil Steril 1988; 49:964-8.
41. Hu SK, Mitcho YI, Rath NC. Effect of estradiol on interleukin-1 synthesis by macrophages. Int J Immunopharmacol 1988;10:247-52.
42. McCurden AB, Stimson WH. Sex hormones and immune function. In: Ader R, Cohen N, eds. Psychoimmunology. 2nd ed. New York, Academic Press 1991:475-93.
43. Chao TC, Van Alten PJ, Greager JA, Walter RJ. Steroid sex hormones regulate the release of tumor necrosis factor by macrophages. Cell Immunol 1995;160:43-9.
44. Wira CR, Sandoe CP. Sex steroid hormone regulation of immunoglobulin G (IgG) and A (IgA) in rat uterine secretions. Nature 1977;268:534-6.
45. Wira CR, Sullivan DA. Estradiol and progesterone regulation of immunoglobulin A and G and secretory component in cervicovaginal secretions of the rat. Biol Reprod 1985;32: 90-5.
46. Sullivan DA, Underdown BJ, Wira CR. Steroid hormone regulation of free secretory component in the rat uterus. Immunology 1983;49:379-86.
47. Parr MEl, Parr EL. Mucosal immunity in the female and male reproductive tracts. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Handbook of mucosal immunology. San Diego, CA: Academic Press, 1994:677-89.
48. McDermott MR, Clark DA, Bienenstock J. Evidence of a common mucosal immunologic system. II Influence of the estrous cycle on B immunoblast migration into genital and intestinal tissues. J Immunol 1980;124:2536-9.
49. Canning MB, Billington WD. Hormonal regulation of immunoglobulin and plasma cells in the mouse uterus. J Endocrinol 1983;97:419-24.
50. Rachman F, Casimiri V, Psychoyos A, Bernard O. Immunoglobulins in the mouse uterus during the oestrous cycle. J Reprod Fertil 1983;69:17-21.
51. Wira CR, Richardson J, Prabhala R. Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In: Ogra PL, Mestecky J, Lamm ME, Strober W. McGhee JR, Bienenstock J, eds. Handbook of mucosal immunology. San Diego, CA: Academic Press, 1994:705-18.
52. Gallichan WS, Rosenthal KL. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunised female mice against herpes simplex virus type 2 infection in the genital tract. Virology 1996;224:487-97.
53. Suzuki M, Ogawa M, Tamada T, Nagura H, Watanabe K. Immunohistochemical localization of secretory component and IgA in human endometrium in relation to menstrual cycle. Acta Histochem Cytochem 1984;17:223-9.
54. Usala SJ, Usala FO, Haciski R, Holt JA, Schumacher GF. IgG and IgA content of vaginal fluid during the menstrual cycle. J Reprod Med 1989;34:292-4.
55. Sullivan DA, Richardson GS, MacLaughlin DT, Wira CR. Variations in the levels of secretory component in human uterine fliud during the menstrual cycle. J Steroid Biochem 1984;20:509-13.
56. Prabhala RH, Wira CR. Sex hormone and IL-6 regulation of antigen presentation in the female reproductive tract mucosal tissues. J Immunol 1995;155:5566-73.
57. Wira CR, Rossoll RM. Antigen-presenting cells in the female reproductive tract: influence of sex hormones on antigen presentation in the vagina. Immunology 1995;84: 505-8.
58. Weinberger O, Herrmann S, Mescher MF, Benacerraf B, Burakaff SJ. Antigen presenting cell function in induction of helper T cells for cytotoxic T-lymphocyte responses: evidence for antigen processing. Proc Natl Acad Sci USA 1981;78:1796-9.
59. Chesnut RW, Gray HM. Antigen presenting cells and mechanisms of antigen presentation. Crit Rev Immunol 1985;5:263-316.
60. Head JR, Gaede SD. Ia antigen expression in the rat uterus. J Reprod Immunol 1986;9:137-53.
61. Bjercke S, Brandtzaeg P. Glandular distribution of immunoglobulins, J chain, secretory component, and HLA-DR in the human endometrium throughout the menstrual cycle. Hum Reprod 1993;8:1420-5.
62. Tabibzadeh SS. Evidence of T cell activation and potential cytokine action in human endometrium. J din Endocrinol Metab 1990;71:645-9.
63. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-g promoter. J Immunol 1991;146:4362-7.
64. Tabibzadeh SS, Santanam U, Sehgal PB, May LT. Cytokine induced production of IFN-β2/IL-6 by freshly explanted human endometrial stromal cells: modulation by estradiol-17-b. J Immunol 1989;142:3134-9.
65. De M, Sanford TR, Wood GW. IL-1, IL-6 and TNF-α are produced in the mouse uterus during the estrous cycle and are induced by estrogen and progesterone. Dev Biol 1992; 154:297-305.
66. Jacobs AL, Sehgal PB, Julian J, Carson DD. Secretion and hormonal regulation of IL-6 production by mouse uterine stromal and polarised epithelial cells cultured in vitro. Endocrinology 1992;131:1037-46.
67. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagos SC. 17β-Estradiol inhibits expression of human IL-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994;93:944-50.
68. Sweet RL, Blankfort-Doyle M, Robie MO, Schachter J. The occurrence of chlamydial and gonococcal salpingitis during the menstrual cycle. JAMA 1986;255:2062-4.
69. Britigan BE, Cohen MS, Sparling PF. Gonococcal infection: a model of molecular pathogenesis. N Engl J Med 1985;313:1683-4.
70. Holmes KK, Counts GW, Beaty HN. Disseminated gonococcal infection. Ann Intern Med 1971;74:979-93.
71. Eschenbach DA, Harnisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977;128:838-50.
72. Keith L, Moss W, Berger GS. Gonorrhoea detection in a family planning clinic: a cost benefit analysis of 2,000 triplicate cultures. Am J Obstet Gynecol 1975;121:399-404.
73. Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the high risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 1989;160:396-402.
74. Braude AI, Corbeil LB, Levine S, Ito J, McCutchan JA. Possible influence of cyclical menstrual changes on resistance to the gonococcus. In: Brooks GF, ed. Immunobiology of Neisseria gonorrhoeae. Washington DC: American Society of Microbiology, 1978:328-37.
75. Taylor-Robinson D, Furr PM, Hetherington CM. Neisseria gonorrhoeae colonises the genital tract of oestradiol-treated germ-free female mice. Microb Pathogen 1990;9:369-74.
76. Kita E, Takahashi S, Yasui K, Kashiba S. Effect of estrogen (17β-estradiol) on the susceptibility of mice to disseminated gonococcal infection. Infect Immun 1985;49:238-43.
77. Gorby GL, Clemens CM, Barley LEt, McGee ZA. Effect of human chorionic gonadotrophin (hCG) on Neisseria gonorrhoeae invasion of and IgA secretion by human fallopian tube mucosa. Microbial Pathogenesis 1991;10:373-84.
78. Oram JD, Reiter B. Inhibition of bacteria by lactoferrin and other iron chelating agents. Biochem Biophys Acta 1968; 170:351-6.
79. Arnold RR, Cole MF, McGhee JR. A bactericidal effect for human lactoferrin. Science 1977;19:263-5.
80. Cohen MS, Britigan BE, French M, Bean K. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987;157: 1122-5.
81. Mardh PA, Westrom L. Adherence of bacteria to vaginal epithelial cells. Infect Immun 1976;13:661-6.
82. Sobel JD, Schneider J, Kaye D, Levison ME. Adherence of bacteria to vaginal epithelial cells at various times in the menstrual cycle. Infect Immun 1981;32:194-7.
83. Forslin L, Danielsson D, Falk V. Variations in attachment of Neisseria gonorrhoeae to vaginal epithelial cells during the menstrual cycle and early pregnancy. Med Microbiol Immunol 1979;167:231-8.
84. Elgaali A, Mahmoud EA, Hamad EE, Olsson SE, Mardh P-A. Antichlamydial activity of cervical secretion in different phases of the menstrual cycle and the influence of hormonal contraceptives. Contraception 1994;49:265-74.
85. Washington AK, Gove S, Schachter J, et al. Oral contraceptives, Chlamydia trachomatis, and pelvic inflammatory disease. JAMA 1985;253:2246-50.
86. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: a quantitative review. Genitourin Med 1992;68:209-16.
87. Wolner-Hanssen P, Eschenbach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990;263:54-9.
88. Ness RB, Keder LM, Soper DE, et al. Oral contraception and the recognition of endomecritis. Am J Obstet Gynecol 1997;176:580-5.
89. Crowley T, Homer P, Hughes A, et al. Hormonal factors and the laboratory detection of Chlamydia trachomatis in women: implications for screening. Im J STD AIDS 1997; 8:25-31.
90. Bose SK, Goswami PC. Enhancement of adherence and growth of Chlamydia trachomatis by estrogen treatment of HeLa cells. Infect Immun 1986;53:646-50.
91. Moses EB, Peck EJ Jr, Barron AL. Enhancement of growth of the chlamydial agent of guinea pig inclusion conjunctivitis in HeLa cells by estradiol. Curr Microbiol 1984;11:265-8.
92. Sugarman B, Agbor P. Estrogens and Chlamydia trachomatis. Proc Soc Exp Biol Med 1986;183:125-31.
93. Maslow AS, Davis CH, Choong J, Wyrick PB. Estrogen enhances attachment of Chlamydia trachomatis to human endometrial epithelial cells in vitro. Am J Obstet Gynecol 1988;159:1006-14.
94. Pasley JN, Rank RG, Hough AJ, Cohen C, Barron AL. Absence of progesterone effects on chlamydial genital infection in female guinea pigs. Sex Transm Dis 1985;12: 155-8.
95. Barron AL, Pasley JN, Rank RG, White HJ, Mrak RE. Chlamydial salpingitis in female guinea pigs receiving oral contraceptives. Sex Transm Dis 1988;15:169-73.
96. Rank RG, Sanders MM, Kidd AT. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pig model of pelvic inflammatory disease. Am J Path 1993;142:1291-6.
97. Ito JI, Harrison HR, Alexander ER, Billings LJ. Establishment of genital tract infection in the CF-1 mouse by intravaginal inoculation of a human oculogenital isolate of Chlamydia trachomatis. J Infect Dis 1984;150:577-82.
98. Tuffrey M, Falder P, Taylor-Robinson D. Genital tract infection and disease in nude and immunologically competent mice after inoculation of a human strain of Chlamydia trachomatis. Br J Exp Pathol 1982;63:539-46.
99. Patton DL, Cosgrove Sweeney YT, Kuo CC. Oral contraceptives do not alter the course of experimentally induced chlamydial salpingitis in monkeys. Sex Transm Dis 1994;21:89-92.
100. Sugarman B, Mummaw N. The effect of hormones on Trichomonas vaginalis. J Gen Microbiol 1988;134:1623-8.
101. Sugarman B, Mummaw N. Oestrogen binding by and effect of oestrogen on trichomonads and bacteria. J Med Microbiol 1990;32:227-32.
102. Ford LC, Hammill HA, DeLange RG, et al. Determination of estrogen and androgen receptors in Trichomonas vaginalis and the effects of antihormones. Am J Obstet Gynecol 1987;156:1119-21.
103. Sugarman B, Mummaw N. Effects of antimicrobial agents on growth and chemotaxis of Trichomonas vaginalis. Antimicrob Agents Chemother 1988;32:1323-6.
104. Azuma T. A study of the parasitizing condition of Trichomonas vaginalis with special reference to the relationship between estrogen and the growth of Trichomonas vaginalis. J Jap Obstet Gynec Soc 1968;15:168-72.
105. el-Boulaqi HA, el-Refaie SA, Bassiouny GA, Amin FMA. The relation between Trichomonas vaginalis and contraceptive measures. J Egypt Soc Parasitol 1984;14:495-9.
106. Cappuccinelli P, Lanes C, Cagliani I, Negro Ponzi A. Features of intravaginal Trichomonas vaginalis infection in the mouse and the effect of oestrogen treatment and immunosuppression. G Batteriol Virol Immunol 1974;67:31-40.
107. Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvo-vaginal candidiasis. Clin Microbiol Rev 1996;9:335-48.
108. Powell BL, Drutz DI. Estrogen receptor in Candida albicans: a possible explanation for hormonal influences in vaginal candidiasis. Abstr 751, p222. In: Program and abstracts of the 23rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1983.
109. Larsen B, Galask RP. Influence of estrogen and normal flora on vaginal candidiasis in the rat. J Reprod Med 1984; 29:863-8.
110. Kinsman OS, Collard AE. Hormonal factors in vaginal candidiasis in rats. Infect Immun 1986;53:498-504.
111. Kinsman OS, Pitblado K, Coulson CJ. Effect of mammalian steroid hormones and luteinising hormone on the germination of Candida albicans and implications for vaginal candidiasis. Mycoses 1988;31:617-26.
112. Skowronski R, Feldman D. Characterisation of an estrogen binding protein in the yeast Candida albicans. Endocrinology 1989;124:1965-72.
113. Loose DS, Schurman D, Feldman D. A corticosteroid binding protein and endogenous ligand in Candida albicans indicating a possible steroid receptor system. Nature 1981;293:477-9.
114. Loose DS, Feldman D. Characterisation of a unique corticosteroid binding protein in Candida albicans. J Biol Chem 1982;257:4925-30.
115. Madani ND, Malloy PJ, Rodriguez-Pombo P, Krishnan P, Feldman D. Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. Proc Natl Acad Sci USA 1994;91:922-6.
116. Kalo-Klein A, Witkin SS. Regulation of the immune response to Candida alhicans by monocytes and progesterone. Am J Obstet Gynecol 1991;164:1351-4.
117. Nohmi T, Abe S, Dohashi K, Tansho S, Yamaguchi H. Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women's vulnerability to vaginal candidiasis. Microbiol Immunol 1995;39:405-9.
118. Dennerstein G. Depo-provera in the treatment of recurrent vulvo-vaginal candidiasis. J Reprod Med 1986;31:801-3.
119. White DJ, Johnson EM, Warnock DW. Management of persistent vulvo-vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993;69:112-4.
120. Iwasaka T, Wada T, Sugimori H. Enhancement of colonization of Ureaplasma urealyticum in the mouse genital tract by estrogen treatment. Am J Obstet Gynecol 1986;155: 1124-7.
121. Furr PM, Taylor-Robinson D. The establishment and persistence of Ureaplasma urealyticum in oestradiol-treated female mice. J Med Microbiol 1989;29:111-4.
122. Furr PM, Taylor-Robinson D. Oestradiol-induced infection of genital tract female mice by Mycoplasma hominis. J Gen Microbiol 1989;135:2743-9.
123. Furr PM, Hetherington CM, Taylor-Robinson D. The susceptibility of germ-free, oestradiol-treated mice to Mycoplasma hominis. J Med Microbiol 1989;30:233-6.
124. Furr PM, Taylor-Robinson D. Enhancement of experimental pulmonis infection of the mouse genital tract by progesterone treatment. J Hyg 1984;92:139-44.
125. Furr PM, Taylor-Robinson D. The contrasting effects of progesterone and oestrogen on susceptibility of mice to genital infection with Mycoplasma pulmonis. J Med Microbiol 1993;38:160-5.
126. Taylor-Robinson D, Furr PM. Elimination of mycoplasmas from the murine genital tract by hormone treatment. Epidemiol Infect 1990;105:163-8.
127. Furr PM, Taylor-Robinson D. Factors influencing the ability of different mycoplasmas to colonize the genital tract of hormone-treated female mice. Int J Exp Path 1993;74:97-101.
128. Furr PM, Taylor-Robinson D. The influence of hormones on the bacterial flora of the murine vagina and implications for human disease. Microb Ecol Health Dis 1991;4:141-8.
129. Koiter TR, Hazenberg MP, Van der School P. Regulation of bacterial flora of the vagina in cyclic female rats. J Exp Zool 1977;202:121-8.
130. Larsen B, Markovetz Al, Galask RP. Quantitative alterations in the genital microflora of female rats in relation to the estrous cycle. J Infect Dis 1976;134:486-9.
131. Larsen B. Markovetz AJ, Galask RP. Relationship of vaginal cytology to alterations of vaginal microflora of rats during the estrous cycle. Appl Env Microbiol 1977;33:556-62.
132. Bartlett JG, Onderdonk AB, Drude E, et al. Quantitative bacteriology of the vaginal flora. J Infect Dis 1977;136:271-7.
133. Sautter RL, Brown WJ. Sequential vaginal cultures from normal young women. J Clin Microbiol 1980;11:479-84.
134. Nearly MP, Allen J, Okubadejo OA, Payne DJH. Preoperative vaginal bacteria and post-operative infections in gynaecological patients. Lancet 1973;ii:1291-4.
135. Levison ME, Corman LC, Carrington ER, Kaye D. Quantitative microflora of the vagina. Am J Obstet Gynecol 1977; 127:80-5.
136. Kornman KS, Loesche WJ. Effects of estradiol and progesterone on Bacteroides melaninogenicus and Bacteroides gingivalis. Infect Immun 1982;35:256-63.
137. Hooton TM, Winter C, Tiu F, Stamm WE. Association of acute cystitis with the stage of the menstrual cycle in young women. Clin Infect Dis 1996;23:635-6.
138. Lang, WR. Vaginal acidity and pH: a review. Obstet Gynecol Surv 1955;10:546-60.
139. Molander U, Milsom I, Ekelund P, Mellstrom D, Eriksson O. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post menopause. Maturitas 1990;12:113-20.
140. Mardh P-A, Soltesz LV. In vitro interaction between lactobacilli and microorganisms occuring in the vaginal flora. Scand J Infect Dis (Suppl) 1983;40:47-51.
141. Stamey TA, Sexton CC. The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol 1975;113:214-7.
142. Bergstrom H. Estriol in recurrent urinary tract infection in elderly women? Acta Obstet Gynecol Scan (Suppl) 1987;140: 79-83.
143. Mulholland SG, Qureshi SM, Fritz RW, Silverman H. Effect of hormonal deprivation on the bladder defense mechanism. J Urol 1982;127:1010-3.
144. Parsons CL, Schmidt JD. Control of recurrent lower urinary tract infection in the postmenopausal woman. J Urol 1982;128:1224-6.
145. Brandberg A, Meilstrom D, Samside G. Low dose oral estriol treatment in elderly women with urogenital infections. Acta Obstet Gynecol Scand (Suppl) 1987;140:33-8.
146. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post menopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
147. Harle EMJ, Bullen JJ, Thomson DA. Influence of oestrogen on experimental pyelonephritis caused by Escherichia coli. Lancet 1975;ii:283-6.
148. Corriere JN Jr, Murphy JJ. The effect of oestrogen upon ascending urinary tract infection in rats. Br J Urol 1968;40: 306-14.
149. Riedasch G, Setzis K, Bersch W, Ritz E. Estrogens influence antibody coating in experimental urinary tract infection. Klin Wochenschr 1983;61 :529-31.
150. Schaeffer AJ, Amundsen SK, Schmidt LN. Adherence of Escherichia coli to human urinary tract epithelial cells. Infect Immun 1979;24:753-9.
151. Sharma S, Madhur BS, Singh R, Sharma BK. Effect of contraceptives on the adhesion of Escherichia coli to uroepithelial cells. J Infect Dis 1987;156:490-4.
152. Sobel JD, Kaye D. Enhancement of Escherichia coli adherence to epithelial cells derived from estrogen-stimulated rats. Infect Immun 1986;53:53-6.
153. Venegas MF, Navas EL, Gaffney RA, et al. Binding of type 1-piliated Escherichia coli to vaginal mucus. Infect Immun 1995;63:416-22.
154. Nishikawa Y, Baba T. In vitro adherence of Escherichia coli to endometrial epithelial cells of rats and influence of estradiol. Infect Immun 1985;50:506-9.
155. Nishikawa Y, Baba T, Imori T. Effect of estrous cycle on uterine infection induced by Escherichia coli. Infect Immun 1984;43:678-83.
156. Nishikawa Y, Baba T. Effects of ovarian hormones on manifestation of purulent endometritis in rat uteruses infected with Escherichia coli. Infect Immun 1985;47:311-7.
157. Harris RW, Brinton LA, Cawdell RH, et al. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer 1980;42:359-69.
158. Brinton LA, Muggins GR, Lehman HF, et al. Long term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986;38:339-44.
159. Jones CJ, Brinton LA, Hamman RF, et al. Risk factors for in situ cervical cancer: results from a case-control study. Cancer Res 1990;50:3657-62.
160. Vessey MP, McPherson K, Lawless M, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983;ii:930-4.
161. Brisson J, Morin C, Roy M, et al. Risk factors for cervical intraepithelial neoplasia: differences between low-and high-grade lesions. Am J Epidemiol 1994;140:700-10.
162. Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer 1987;40:198-201.
163. Pater A, Bayatpour M, Pater MM. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 1990;162:1099-103.
164. Cook T, Storey A, Almond N, Osborne K, Crawford L. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci USA 1988;85:8820-4.
165. Gloss B, Bernard HU, Seedorf K, Klock G. The upstream regulatory region of the human papillomavirus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987;6:3735-43.
166. Pater MM, Mittal R, Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 1994;2:229-34.
167. Mitrani-Rosenbaum S, Tsvieli R, Tu-Kuspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989;70:2227-32.
168. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumour incidence and presence of mammary tumour virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 1985;82:6295-9.
169. Auborn KJ, Woodworm C, DiPaolo JA, Bradlow HL. The interaction between human papillomavirus infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991;49:867-9.
170. Quarmby VE, Korach KS. Differential regulation of protein synthesis by estradiol in uterine component tissues. Endocrinology 1984;114:694-702.
171. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 1996;93:2930-5.
172. Gould SF, Shannon JF, Cunha GR. The autoradiographic demonstration of estrogen binding in normal human cervix and vagina during the menstrual cycle, pregnancy and the menopause. Am J Anat 1983;168:229-38.
173. Ciocca DR, Puy LA, Lo Castro G. Localisation of an estrogen-responsive protein in the human cervix during menstrual cycle, pregnancy, and menopause and in abnormal cervical epithelia without atypia. Am J Obstet Gynecol 1986;155:1090-6.
174. Monsenego J, Magdelenat H, Catalan F, et al. Estrogen and progesterone receptors in cervical human papillomavirus related lesions. Im J Cancer 1991;48:533-9.
175. Henry RJW, Goodman JDS, Godley M, et al. Immunohistochemical study of cytoplasmic oestradiol receptor in nor-mal, dysplastic and malignant cervical tissue. Br J Obstet Gynaecol 1988;95:927-32.
176. Gao YL, Twiggs L, Leung B, et al. Cytoplasmic estrogen and progesterone receptors in primary cervical carcinoma: clinical and histopathologic correlates. Am J Obstet Gynecol 1983;146:299-306.
177. Negrini BP, Schiffman MH, Kurman RJ, et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res 1990;50:4670-5.
178. Fenton J, Asselain B, Magdelenat H. Estrogen and progesterone receptors in carcinoma of the uterine cervix (estimation in 101 cases). Bull Cancer 1986;73:124-6.
179. Ng ABP, Reagan JW, Yen SSC. Herpes genitalia: clinical and cytopathologic experience with 256 patients. Obstet Gynecol 1970;36:645-51.
180. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episode of genital herpes. Relation to HSV type and antibody response. N Engl J Med 1981;305:315-9.
181. Guinan ME, MacCalman J, Kern ER, Overall JC, Spruance SL. The course of untreated recurrent genital herpes simplex infection in 27 women. N Engl J Med 1981; 304:759-63.
182. Mindel A, Coker DM, Faherty A, Williams P. Recurrent genital herpes: clinical and virological features in men and women. Genitourin Med 1988;64:103-6.
183. Nahmias AJ, Josey WE, Naib ZM, et al. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 1971;110:825-37.
184. Overall JC, Kern ER, Schlitzer RL, Friedman SB, Glasgow LA. Genital Herpesvirus hominis infection in mice. 1 Development of an experimental model. Infect Immun 1975;11:476-80.
185. Baker DA, Plotkin SA. Enhacement of vaginal infection in mice by herpes simplex virus type II with progesterone. Proc Soc Exp Biol Med 1978;158:131-4.
186. Murr SM, Stabenfeldt GH, Bradford GE, Geschwind II. Plasma progesterone during pregnancy in the mouse. Endocrinology 1974;94:1209-11.
187. Baker DA, Phillips CA, Roessner K, Albertini RJ, Mann LJ. Suppression by progesterone of nonspecific in vitro lymphocyte stimulation in mice as a mechanism for the enhancement of herpes simplex virus type 2 vaginal infection. Am J Obstet Gynecol 1980;136:440-5
188. Teepe AG, Allen LB, Wordinger J, Harris EF. Effect of the estrous cycle on susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2. Antiviral Res 1990;14:227-36.
189. Sonnex C. Recurrent genital tract infection: a result of induced immunosuppression? Genitourin Med 1989;65: 372-5.